Insilico, a company that pioneered the use of artificial intelligence in pharmaceuticals, has laid out an ambitious two-part mission: become the No. 1 drugmaker in China and develop what it calls a "God-like" drug to extend human life.
According to reporting carried by MSN and the Hindustan Times, Insilico was the first company to use generative AI to develop a drug that reached clinical trials. The same reports say the firm is now betting that longevity treatments — therapies aimed at slowing aging — will fuel its next phase of growth.
The scale of that ambition is striking. According to NewsBytes, Insilico is pursuing a breakthrough drug intended to push human lifespan as far as 150 years, while simultaneously trying to dominate China's pharmaceutical market.
The company's focus sits inside a fast-growing field. According to a market research study published by Healthcare Foresights and reported by Yahoo Finance, the global in silico clinical trials market — which uses computer modeling and simulation rather than only traditional lab and human testing — was valued in the billions and is projected to reach USD 8.94 billion by 2035, growing at a compound annual rate of 15.2 percent.
Generative AI, the same technology behind chatbots, is being applied here to design candidate molecules and speed up the early stages of drug discovery, which have traditionally taken years and enormous sums of money. Insilico's claim to being first to carry an AI-generated drug into human trials is what makes its longevity push notable rather than purely speculative.
Why it matters: if AI can reliably shorten the path from idea to tested medicine, it could reshape how — and how cheaply — new drugs reach patients, and Insilico's longevity bet is an early test of just how far those tools can be pushed.